Their cancer antibody was tested in a way I have never heard which was against the SOC (assumption) in lab testing on mice. It outperformed it significantly. It was also human compatible. That's a big deal in mice testing. The next round will be on humanized mice. I expect that testing to be even better. It had a 98.8% cure rate and conferred immunity to return cancers. Unheard of in my experience but I am a doc, not a lab expert. Cancer is the hottest secote and if this data confirms, with big pharma already involved I expect partnership at the minimum. This should be by eom October. The patent is also pending but as a proprietary compound, should be approved. They also have 2 other similar cancer compounds developed.
Their proprietary non opoid pain reliever is already patented. Their recent hire has huge NFL connections and should facilitate the marketing of this drug. Not sure what the possibilities are here honestly but I like the fact that they are monetizing multiple avenues which again is a rarity down here. And it won't take much revenue to change the valuation significantly. Non opoid medicines is also a huge revenue area right now.
Recent dilution completed. Cash on hand. Q much improved. Technicals very bullish.
Jmho
News 
Market Data 
Discover 
AI
